Stock listing
Tradegate:UR8 UroGen Pharma Ltd. Aktie
German listing (Tradegate) of UroGen Pharma Ltd. · home listing NASDAQ:URGN
Follow UroGen Pharma Ltd. into a list and get an email when it puts out news.
Home listing price · NASDAQ:URGN
$32.72 USD -0.76 (-2.3%)
Close on Oct 30, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:URGN
- Day range
- $32.39 – $33.65 USDOct 30, 2026
- Volume
- 1.17M sharesOct 30, 2026
- Market cap
- $1.60B USDAt the close on Oct 30, 2026 · price × 48.88M shares outstanding
- 52-week range
- $16.50 – $50.81 USDLowest and highest trades, Oct 31, 2025 – Oct 30, 2026
- Traded on an average day
- $39.17M USDMedian day 762,150 shares · last 3 months, Jul 30, 2026 – Oct 30, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:URGN · Home | $32.72 USD | -0.76 (-2.3%) | 1,166,116 | $33.14 | $33.65 | $32.39 | $33.48 | Close on Oct 30, 2026 |
| LSE:0XOD | $33.90 USD | -1.05 (-3.0%) | 231 | $34.20 | $34.50 | $33.50 | $34.95 | Close on Oct 27, 2026 |
| Frankfurt:UR8 | €29.45 EUR | -1.05 (-3.4%) | — | €29.45 | €29.45 | €29.45 | €30.50 | Close on Oct 30, 2026 |
Daily closes
Last 3 months, Jul 30, 2026 – Oct 30, 2026 · NASDAQ:URGN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $32.72 | -0.76 | -2.3% | $33.14 | $33.65 | $32.39 | 1,166,116 | |
| $33.48 | -0.27 | -0.8% | $33.79 | $34.93 | $32.96 | 1,424,444 | |
| $33.75 | -0.16 | -0.5% | $33.66 | $34.04 | $33.10 | 1,587,964 | |
| $33.91 | -0.13 | -0.4% | $34.16 | $34.50 | $33.50 | 1,030,332 | |
| $34.04 | -0.45 | -1.3% | $34.64 | $35.00 | $33.87 | 660,404 | |
| $34.49 | -0.66 | -1.9% | $34.44 | $35.02 | $33.80 | 738,100 | |
| $35.15 | -0.33 | -0.9% | $35.23 | $35.98 | $34.11 | 689,100 | |
| $35.48 | +0.47 | +1.3% | $35.25 | $36.46 | $35.05 | 777,000 | |
| $35.01 | +0.86 | +2.5% | $34.05 | $35.70 | $34.00 | 747,800 | |
| $34.15 | -0.41 | -1.2% | $34.75 | $35.48 | $33.40 | 1,269,300 | |
| $34.56 | -2.05 | -5.6% | $36.35 | $36.91 | $34.26 | 1,057,200 | |
| $36.61 | +0.03 | +0.1% | $37.04 | $38.37 | $36.27 | 636,500 | |
| $36.58 | -1.68 | -4.4% | $37.96 | $39.09 | $36.44 | 1,079,700 | |
| $38.26 | -0.02 | -0.1% | $37.82 | $38.84 | $37.30 | 759,900 | |
| $38.28 | +1.45 | +3.9% | $36.97 | $38.32 | $36.20 | 531,000 | |
| $36.83 | -0.15 | -0.4% | $36.97 | $38.11 | $36.69 | 3,895,600 | |
| $36.98 | -3.72 | -9.1% | $39.93 | $40.05 | $34.18 | 2,016,300 | |
| $40.70 | -0.73 | -1.8% | $40.70 | $41.93 | $40.64 | 486,200 | |
| $41.43 | -1.35 | -3.2% | $43.24 | $43.54 | $41.10 | 764,400 | |
| $42.78 | +1.38 | +3.3% | $41.38 | $42.91 | $40.50 | 1,276,500 | |
| $41.40 | +0.85 | +2.1% | $40.93 | $41.82 | $40.05 | 597,600 | |
| $40.55 | -0.08 | -0.2% | $40.63 | $41.26 | $40.10 | 624,600 | |
| $40.63 | +0.18 | +0.4% | $40.72 | $41.10 | $40.09 | 641,400 | |
| $40.45 | -0.45 | -1.1% | $40.50 | $41.69 | $39.75 | 642,800 | |
| $40.90 | -0.45 | -1.1% | $40.74 | $41.33 | $40.32 | 1,165,600 | |
| $41.35 | +0.12 | +0.3% | $41.23 | $41.78 | $40.65 | 655,300 | |
| $41.23 | -0.40 | -1.0% | $41.24 | $41.62 | $39.90 | 1,074,400 | |
| $41.63 | -1.13 | -2.6% | $42.72 | $42.72 | $39.72 | 1,298,400 | |
| $42.76 | -0.44 | -1.0% | $43.58 | $44.08 | $42.60 | 394,600 | |
| $43.20 | -0.05 | -0.1% | $44.00 | $44.00 | $42.53 | 482,400 | |
| $43.25 | -0.70 | -1.6% | $44.00 | $44.25 | $43.15 | 703,100 | |
| $43.95 | +0.46 | +1.1% | $44.82 | $45.33 | $43.15 | 699,400 | |
| $43.49 | +1.75 | +4.2% | $42.07 | $43.72 | $42.07 | 997,200 | |
| $41.74 | -0.90 | -2.1% | $43.25 | $43.25 | $41.09 | 545,800 | |
| $42.64 | +0.33 | +0.8% | $42.36 | $43.72 | $41.65 | 521,900 | |
| $42.31 | +0.07 | +0.2% | $43.13 | $43.61 | $41.60 | 687,200 | |
| $42.24 | -2.76 | -6.1% | $44.25 | $44.48 | $41.85 | 688,700 | |
| $45.00 | +1.185 | +2.7% | $43.82 | $47.06 | $43.77 | 1,019,500 | |
| $43.82 | -0.275 | -0.6% | $43.24 | $44.72 | $42.50 | 727,700 | |
| $44.09 | -0.79 | -1.8% | $44.54 | $45.10 | $43.50 | 779,000 | |
| $44.88 | +0.46 | +1.0% | $44.37 | $45.63 | $43.45 | 877,800 | |
| $44.42 | +1.03 | +2.4% | $44.01 | $45.88 | $43.49 | 473,500 | |
| $43.39 | +0.30 | +0.7% | $42.59 | $43.56 | $42.52 | 584,200 | |
| $43.09 | -0.53 | -1.2% | $43.17 | $44.86 | $42.00 | 749,000 | |
| $43.62 | -1.88 | -4.1% | $45.09 | $45.54 | $43.39 | 580,000 | |
| $45.50 | -0.44 | -1.0% | $46.13 | $46.51 | $45.29 | 559,800 | |
| $45.94 | -0.42 | -0.9% | $46.00 | $46.64 | $45.36 | 620,300 | |
| $46.36 | +0.20 | +0.4% | $46.65 | $47.17 | $45.67 | 570,156 | |
| $46.16 | -0.70 | -1.5% | $46.52 | $47.05 | $45.27 | 849,685 | |
| $46.86 | +0.06 | +0.1% | $47.13 | $47.28 | $45.60 | 755,600 | |
| $46.80 | -3.49 | -6.9% | $49.71 | $49.71 | $46.20 | 1,122,400 | |
| $50.29 | +1.37 | +2.8% | $49.89 | $50.81 | $48.55 | 2,389,400 | |
| $48.92 | -0.22 | -0.4% | $48.93 | $49.56 | $48.41 | 823,700 | |
| $49.14 | +0.92 | +1.9% | $48.51 | $49.51 | $48.16 | 1,295,500 | |
| $48.22 | +0.10 | +0.2% | $47.68 | $48.48 | $46.62 | 458,100 | |
| $48.12 | -0.88 | -1.8% | $49.60 | $49.60 | $47.67 | 860,000 | |
| $49.00 | +1.89 | +4.0% | $47.49 | $49.67 | $47.12 | 1,581,100 | |
| $47.11 | +0.80 | +1.7% | $45.61 | $47.33 | $45.52 | 876,600 | |
| $46.31 | -0.65 | -1.4% | $46.74 | $46.89 | $45.34 | 644,600 | |
| $46.96 | +1.36 | +3.0% | $47.23 | $48.19 | $45.75 | 1,026,500 | |
| $45.60 | -0.83 | -1.8% | $46.14 | $48.03 | $45.51 | 1,217,000 | |
| $46.43 | +6.51 | +16.3% | $42.17 | $47.84 | $40.41 | 2,480,600 | |
| $39.92 | +1.33 | +3.4% | $39.29 | $40.46 | $38.81 | 734,500 | |
| $38.59 | +0.35 | +0.9% | $37.71 | $39.41 | $36.68 | 964,700 | |
| $38.24 | -2.85 | -6.9% | $41.10 | $41.11 | $38.01 | 814,700 | |
| $41.09 | +0.64 | +1.6% | $40.32 | $41.61 | $40.32 | 778,800 |
- Ticker
- Tradegate:UR8
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Tradegate
- Currency
- EUR
What changed lately
Latest news release · Oct 28, 2026
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
Latest earnings call · Aug 5, 2026
Urogen Pharma (NASDAQ:URGN) Q2 2026 Earnings Call
Replay and transcript
Latest deck · August 2026
Investor Presentation (August 2026)
Investor deck · 30 slides
Calls
Upcoming
Urogen Pharma (NASDAQ:URGN) Q3 2026 Earnings Call
Wed, Nov 04, 2026 · 10:00 AM ET
Register
Replays
Urogen Pharma (NASDAQ:URGN) Q2 2026 Earnings Call
Wed, Aug 05, 2026 · 10:00 AM ET
Watch TranscriptUrogen Pharma (NASDAQ:URGN) Q1 2026 Earnings Call
Wed, May 06, 2026 · 10:00 AM ET
Watch TranscriptUrogen Pharma (NASDAQ:URGN) Q4 2025 Earnings Call
Mon, Mar 02, 2026 · 10:00 AM ET
Watch Transcript
Latest news
UroGen’s Final Results from Olympus Five-Year Follow-Up Study Reinforces Durable Response with JELMYTO in Patients with Low-Grade Upper Tract Urothelial Cancer
Oct 28, 2026
Closed $33.75 (-0.5%) on Oct 28, 2026
UroGen Pharma to Report Third Quarter 2026 Financial Results on Wednesday, November 4th, 2026
Oct 27, 2026
Closed $33.75 (-0.5%) on Oct 28, 2026
UroGen Announces FDA Acceptance of the New Drug Application for UGN-103, an Investigational Treatment for Adults with Recurrent LG-IR-NMIBC
Oct 19, 2026
Closed $34.15 (-1.2%) on Oct 19, 2026
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies
Aug 20, 2026
Closed $46.80 (-6.9%) on Aug 20, 2026
UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline
Aug 20, 2026
Closed $46.80 (-6.9%) on Aug 20, 2026
UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC
Aug 17, 2026
Closed $49.14 (+1.9%) on Aug 17, 2026
UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights
Aug 5, 2026
Closed $46.43 (+16.3%) on Aug 5, 2026
UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026
Jul 29, 2026
Closed $40.45 (-1.1%) on Jul 29, 2026
UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
Jul 15, 2026
Closed $39.80 (+1.6%) on Jul 15, 2026
Financings
Strategic investment of equity securities
Aug 20, 2026
Announced: up to US$7M
Buyers: UroGen Pharma Ltd. (up to $7 million in the equity securities of IntraGel)
Use of proceeds: Phase 2 clinical development of TumoCure for advanced head and neck cancer
Decks
Investor Presentation (August 2026)
Investor deck · 30 slides · August 2026
Investor Presentation (January 2025)
Investor deck · 44 slides · Jan 14, 2025
Technical Presentation (June 2024)
Technical · 57 slides · Jun 13, 2024
Investor Presentation (March 2024)
Investor deck · 56 slides · Mar 4, 2024
UroGen Pharma Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 31 in the last 12 months · 202 in all · newest Oct 28, 2026 · oldest 2019
- Calls
- 25 calls with a replay · 25 with a transcript · latest Aug 5, 2026
- Decks
- 10 decks · latest August 2026
Where UroGen Pharma Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:URGN · Home listing | NASDAQ | United States | USD |
| LS Exchange:A2DTCV | LS Exchange | Germany | EUR |
| gettex:UR8 | gettex | Germany | EUR |
| Lang & Schwarz:A2DTCV | Lang & Schwarz | Germany | EUR |
| LSE:0XOD | LSE | United Kingdom | USD |
| BOATS:URGN | BOATS | United States | USD |
| Frankfurt:UR8 | Frankfurt | Germany | EUR |
| Dusseldorf:UR8 | Dusseldorf | Germany | EUR |
| Munich:UR8 | Munich | Germany | EUR |
| Stuttgart:UR8 | Stuttgart | Germany | EUR |
| Tradegate:UR8 · This page | Tradegate | Germany | EUR |
Log in to ask 6ix AI your own questions about UroGen Pharma Ltd.